Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 4, 2000, Pages 1020-1026

  Ishigami, Masato ^a   Swertfeger, Debi K ^a   Hui, Michele S ^a   Granholm, Norman A ^a   Hui, David Y ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Apolipoprotein E; Nitric oxide; Smooth muscle cell migration; Smooth muscle cell proliferation

Indexed keywords

APOLIPOPROTEIN E; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; GENE EXPRESSION SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0034090425     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.4.1020     Document Type: Article

References (59)

1. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
2. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1-16.
3. Dory L. Synthesis and secretion of apoE in thioglycolate-elicited mouse peritoneal macrophages: effect of cholesterol efflux. J Lipid Res. 1989; 30:809-816.
4. Mahley RW, Weisgraber KH, Hussain MM, Greenman B, Fisher M, Vogel T, Gorecki M. Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J Clin Invest. 1989;83: 2125-2130.
5. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Gener. 1996;14:55-61.
6. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P. Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol. 1998;274: H1836-H1840.
7. Ishigami M, Swertfeger DK, Granholm N, Hui DY. Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem. 1998;20156-20161.
8. Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway: implications for vascular disease. J Biol Chem. 1997;272:89-95.
9. Vitek MP, Snell J, Dawson H, Colton CA. Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid beta peptide. Biochem Biophys Res Commun. 1997;240:391-394.
10. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest. 1997;100:2146-2152.
11. Joly GA, Schini VB, Vanhoutte PM. Balloon injury and interleukin-1β induce nitric oxide synthase activity in rat carotid arteries. Circ Res. 1992;71:331-338.
12. Hannson GK, Geng YJ, Holm J, Hardhammar P, Wennmalm A, Jennische E. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med. 1994;180:733-738.
13. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett. 1990;275:87-90.
14. Schini VB, Junquero DC, Scott-Burden T, Vanhoutte PM. Interleukin-1beta induces the production of an L-arginine-derived relaxing factor from cultured smooth muscle cells from rat aorta. Biochem Biophys Res Commun. 1991;176:114-121.
15. Geng Y, Hansson GK, Holme E. Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res. 1992;71: 1268-1276.
16. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Anti-atherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 1992;90:1168-1172.
17. Wang BY, Singer AH, Tsao PS, Drexler H, Kosek J, Cooke JP. Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J Am Coll Cardiol. 1994;23:452-458.
18. Aji W, Ravalli S, Szabolcs M, Jiang XC, Sciacca RR, Michler RE, Cannon PJ. L-Arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation. 1997;95: 430-437.
19. Tarry WC, Makhoul RG. L-Arginine improves endothelium dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Arterioscler Thromb. 1994;14:938-943.
20. Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP, Yeung AC. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation. 1997;95:1863-1869.
21. Janssens S, Flaherty D, Nong Z, Varenne O, van Pelt N, Haustermans C, Zoldhelyi P, Gerard R, Collen D. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neo-intima formation after balloon injury in rats. Circulation. 1998;97: 1274-1281.
22. McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ, Akers DL. L-Arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun. 1993;193:291-296.
23. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol. 1994;267:C1405-C1413.
24. Sarkar R, Meinherg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996;78:225-230.
25. Rall SC, Weisgraber KH, Mahley RW. Isolation and characterization of apolipoprotein E. Methods Enzymol. 1986;128:273-287.
26. Hui DY, Innerarity TL, Mahley RW. Defective hepatic lipoprotein receptor binding of B-very low density lipoproteins from type III hypercholesterolemic patients: importance of apolipoprotein E. J Biol Chem. 1984;259:860-869.
27. Davidson WS, Hazlett T, Mantulin WW, Jonas A. The role of apolipoprotein AI domains in lipid binding. Proc Natl Acad Sci U S A. 1996; 93:13605-13610.
28. Geng YJ, Almqvist M, Hansson GK. cDNA cloning and expression of inducible nitric oxide synthase from rat vascular smooth muscle cells. Biochim Biophys Acta. 1994;1218:421-424.
29. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897-1905.
30. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15-N]nitrate in biological fluids. Anal Biochem. 1982;126:131-138.
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
32. Nakayama H, Yokoi H, Fujita J. Quantitation of mRNA by non-radioactive RT-PCR and CCD imaging system. Nucleic Acids Res. 1992; 20:4939.
33. Yokoi H, Natsuyama S, Iwai M, Noda Y, Mori T, Mori KJ, Fujita K, Nakayama H, Fujita J. Non-radioisotope quantitative RT-PCR to detect changes in mRNA levels during early mouse embryo development. Biochem Biophys Res Commun. 1993;195:769-775.
34. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland M, Lancaster JR, McDaniel ML. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 1992;41:552-556.
35. Joly GA, Ayres M, Chelly F, Kilbourn RG. Effects of N(G)-methyl-L-arginine and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun. 1994;199:147-154.
36. Boulanger CM, Heymes C, Benessiano J, Geske RS, Levy BI, Vanhoutte PM. Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. Circ Res. 1998;83:1271-1278.
37. Sarkar R, Gordon D, Stanley JC, Webb RC. Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol. 1997;272: H1810-H1818.
38. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation. 1997;95:1269-1277.
39. Kubo T, Saito E, Hanada M, Kambe T, Hagiwara Y. Evidence that angiotensin II, endothelins and nitric oxide regulate mitogen-activated protein kinase activity in rat aorta. Eur J Pharmacol. 1998;347:337-346.
40. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-1 and platelet derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994;93:1266-1274.
41. Pukac L, Huangpu J, Karnovsky MJ. Platelet-derived growth factor-BB, insulin-like growth factor-1, and phorbol ester activate different signaling pathways for stimulation of vascular smooth cell migration. Exp Cell Res. 1998;242:548-560.
42. Yla-Herttuala S. Expression of lipoprotein receptors and related molecules in atherosclerotic lesions. Curr Opin Lipidol. 1996;7:292-297.
43. Yamamoto T, Bujo H. Close encounters with apolipoprotein E receptors. Curr Opin Lipidol. 1996;7:298-302.
44. Schneider WJ, Nimpf J, Bujo H. Novel members of the low density lipoprotein receptor superfamily and their potential roles in lipid metabolism. Curr Opin Lipidol. 1997;8:315-319.
45. Innerarity TL, Pitas RE, Mahley RW. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J Biol Chem. 1979;254:4186-4190.
46. Riddell DR, Vinogradov DV, Stannard AK, Chadwick N, Owen JS. Identification and characterization of LRP8 (apoER2) in human blood platelets. J Lipid Res. 1999;40:1925-1930.
47. Harmony JAK, Hui DY. Inhibition by membrane-bound low density lipoproteins of the primary inductive events in mitogen stimulated lymphocytes. Cancer Res. 1981;41:3799-3802.
48. Curtiss LK, Edgington TS. Identification of a lymphocyte surface receptor for low density lipoprotein inhibitor, an immunoregulatory species of normal human serum low density lipoprotein. J Clin Invest. 1978;61:1298-1308.
49. Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem. 1998;273:33556-33560.
50. Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J. Reeler/disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and apoE receptor 2. Cell. 1999;97:689-701.
51. Goretzki L, Mueller BM. Low density lipoprotein receptor related protein (LRP) interacts with a GTP-binding protein. Biochem J. 1998;336: 381-386.
52. Misra UK, Chu CTC, Gawdi G, Pizzo SV. The relationship between low density lipoprotein-related protein/alpha2-macroglobulin receptors and the newly described alpha2-M signaling receptor. J Biol Chem. 1994; 269:18303-18306.
53. Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature. 1997;388: 878-881.
54. Wang XS, Gruenstein E. Rapid elevation of neuronal cytoplasmic calcium by apolipoprotein E peptide. J Cell Physiol. 1997;173:73-83.
55. Okada SS, Grobmyer SR, Barnathan ES. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler Thromb Vasc Biol. 1996;16:1269-1276.
56. Wijnberg MJ, Quax PHA, Nieuwenbroek NME, Verheijen JH. The migration of human smooth muscle cells in vitro is mediated by plasminogen activation and can be inhibited by alpha2-macroglobulin receptor associated protein. Thromb Haemost. 1997;78:880-886.
57. Koyama N, Kinsella MG, Wight TN, Hedin U, Clowes AW. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. Circ Res. 1998;83:305-313.
58. Vogel T, Guo NH, Guy R, Drezlich N, Krutzsch HC, Blake DA, Panet A, Roberts DD. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem. 1994;54:299-308.
59. Fukumoto Y, Shimokawa H, Kozai T, Kadokami T, Kuwata K, Yonemitsu Y, Kuga T, Egashira K, Sueishi K, Takeshita A. Vasculoprotective role of inducible nitric oxide synthase at inflammatory coronary lesions induced by chronic treatment with interleukin-1β in pigs in vivo. Circulation. 1997;96:3104-3111.